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Introduction
Severe sepsis defined as sepsis with acute organ dysfunc-
tion1,2 is associated with high morbidity and mortality
rates despite advances in critical care management.3,4
In the United States, the mortality rate of severe sep-
sis was 30–50%, which increased to 80–90% for septic
shock with multiple organ dysfunction.5 In European
countries, the mortality rate of patients with severe sep-
sis and septic shock in the intensive care unit (ICU)
was 32.2–54.1%.6,7 In China, 28-day mortality for pa-
tients with severe sepsis in the surgical ICU (SICU)
was 44.7%.8
Secondary peritonitis is a common problem in
SICU practice and is mostly caused by intra-abdominal
visceral perforation, acute infection of intra-abdominal
viscera, bowel wall necrosis, post-trauma and post-
operation.9 In most patients, secondary peritonitis re-
solves following prompt operative intervention and
appropriate antimicrobial therapy.10 However, elderly
patients are more likely to develop severe sepsis, hence
prolonged ICU stay and increased mortality.11–13
Albumin is the main determinant of plasma oncotic
pressure. It plays a pivotal role in modulating the dis-
tribution of fluid between compartments. Moreover,
it has many biological properties that may be impor-
tant not only for its physiologic actions but also for its
therapeutic effects. The non-oncotic properties of albu-
min include molecular transportation, free radical scav-
enging, modulation of capillary permeability, neutrophil
adhesion and activation, and hemostatic effects.14 The
rate of albumin synthesis is affected by both nutrition
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and inflammation.15 Patients with severe sepsis and
secondary peritonitis usually suffer from severe hypo-
albuminemia and inflammatory process.
There is controversy regarding albumin administra-
tion among meta-analyses. The meta-analysis performed
by the Cochrane Injuries Group Albumin Reviewers
found no evidence to support the notion that albumin
administration reduces mortality in critically ill patients
with hypovolemia, burns or hypoalbuminemia; in
contrast, they found that albumin might increase mor-
tality.16 Choi et al found no difference in mortality and
pulmonary edema between crystalloid and colloid re-
suscitation.17 The meta-analysis performed by Wilkes
and Navickis18 showed no effect of albumin on mortal-
ity. Two studies have reported the benefit of albumin
administration. Rackow et al19 showed that resuscita-
tion of hypovolemic and septic shock patients with
either 6% hetastarch or 5% albumin was associated
with a lower incidence of pulmonary edema than was
resuscitation with 0.9% saline. Sort et al20 showed that
albumin given to patients with cirrhosis and sponta-
neous bacterial peritonitis in addition to antibiotics
reduced the incidence of renal impairment and death
compared to treatment with antibiotics alone. In addi-
tion, albumin has been shown to be effective in prevent-
ing renal failure in patients with cirrhosis and ascites,
and in reducing mortality in patients with spontaneous
bacterial peritonitis.21,22
The Saline vs. Albumin Fluid Evaluation (SAFE)
trial, looking to settle the disputes through random-
ized controlled trials for mortality in ICU patients,
has shown that the use of albumin for fluid resuscita-
tion resulted in similar outcomes at 28 days.23 In the
SAFE trial, albumin seemed to improve survival in pa-
tients with severe sepsis despite statistical insignificance
(relative risk of death [RR], 0.87; 95% confidence in-
terval [CI], 0.74–1.02; p = 0.09). One meta-analysis
performed by Vincent et al24 reported that albumin
significantly reduced overall morbidity (RR, 0.92; 95%
CI, 0.86–0.98; p = 0.002).
Although the SAFE study revealed no significant
difference in all-cause 28-day mortality between the
albumin group and non-albumin group irrespective of
their baseline albumin concentration, the Bureau of
National Health Insurance in Taiwan has set a more
restrictive policy on albumin administration as many
surgeons continue to recommend albumin use in pa-
tients with severe sepsis due to secondary peritonitis
in their daily practice. Based on the above reasons, we
speculated that these small subsets of ICU patients with
severe sepsis and hypoalbuminemia due to secondary
peritonitis might benefit from albumin administration.
Therefore, we conducted this retrospective study to
investigate whether albumin administration could re-
duce mortality in patients with severe sepsis and hypoal-
buminemia due to secondary peritonitis.
Methods
Patients
This was a retrospective study conducted in the SICU
of a tertiary care hospital. Patients who were diagnosed
with severe sepsis associated with secondary peritonitis
from March 2003 to March 2008 were consecutively
enrolled. The criteria for severe sepsis were those de-
fined by the International Sepsis Definitions Con-
ference.2 In brief, severe sepsis was defined as sepsis
associated with organ dysfunction, hypoperfusion, or
hypotension. Organ dysfunction variables included ar-
terial hypoxemia (PaO2/FIO2 < 300), acute oliguria
(urine output < 0.5 mL/kg/hr for at least 2 hours),
creatinine increase > 0.5 mg/dL, coagulation abnor-
malities (international normalized ratio > 1.5 or acti-
vated partial thromboplastin time > 60 seconds), ileus
(absent bowel sounds), thrombocytopenia (platelet
count < 100,000/μL), and hyperbilirubinemia (plasma
total bilirubin > 4 mg/dL). Tissue perfusion variables
included hyperlactatemia (> 2 mmol/L), and decreased
capillary refilling or mottling. Septic shock was defined
as acute circulatory failure unexplained by other causes,
and acute circulatory failure was defined as persistent ar-
terial hypotension (systolic blood pressure <90mmHg,
mean arterial pressure < 60 mmHg, or a reduction 
in systolic blood pressure > 40 mmHg from baseline
despite adequate volume resuscitation).2 Secondary
peritonitis was diagnosed by either abdominal ultra-
sonography or abdominal computed tomography and
confirmed intraoperatively.
Patients who received a daily minimum of 25 g in-
travenous human albumin for at least 3 days within
the first week of SICU stay were classified into the
study group. Patients who received the daily dosage
of human albumin but who died within 3 days of
SICU admission were also classified into the study
group. Patients who did not receive intravenous hu-
man albumin or whose daily albumin dosage was < 25 g
were classified into the control group. All septic pa-
tients received aggressive fluid resuscitation in addi-
tion to albumin administration. Patients were excluded
if they were pregnant, younger than 18 years, or died
within 24 hours after admission to the SICU. The
study protocol was approved by the institutional
review board of the hospital, and written informed
consent was waived because this was a retrospective
study.
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Data collection
The demographic data of the patients on their admis-
sion to the SICU were collected. The status of acute
organ dysfunction due to severe sepsis was recorded
and compared. The presence of comorbidities and
transfusion of fresh frozen plasma (FFP) were recorded.
Admission severity of illness was estimated by using
the Acute Physiology and Chronic Health Evaluation
II (APACHE II) score, Sequential Organ Failure As-
sessment (SOFA) score, and Multiple Organ Dysfunc-
tion Score (MODS). The patients in each group were
further stratified into 2 strata: baseline serum albumin
concentration ≤ 20 g/L and baseline serum albumin
concentration > 20 g/L. The 28-day mortality rate
was compared.
Statistical analysis
Categorical variables were expressed as absolute num-
ber and relative frequencies, and were compared using
χ2 or Fisher’s exact test when appropriate. Continu-
ous variables with normal distribution were expressed
as mean ± standard deviation and compared using
Student’s t test. Univariate analysis was performed for
the comparison of the risk of death for all baseline
characteristics between the study and control groups
in different strata according to their baseline serum
albumin concentration. Multivariate logistic regression
analysis was performed if the p value of the variable
was < 0.1 on univariate analysis. Survival times were
compared with the use of the log rank test and were
presented as Kaplan–Meier curves.
Results
Patient characteristics
Within the study period, 133 patients were diagnosed
with secondary peritonitis and severe sepsis, and were
admitted to the SICU. There were 52 patients in the
study group and 81 patients in the control group.
Table 1 summarizes the patients’ clinical characteristics.
There were no significant differences in any of the base-
line characteristics between the study and control groups
except for the total amount of albumin administered
in the first 7 days.
Comparison of mortality
Table 2 compares the 28-day mortality rates of the
study and control groups. Among the patients with
baseline serum albumin ≤ 20 g/L, there were 10 (45%)
patients in the study group and 28 (76%) in the control
group who died within 28 days (RR, 0.27; 95% CI,
0.09–0.83; p = 0.03). Albumin significantly reduced
the 28-day mortality rate in patients with secondary
peritonitis and severe sepsis whose baseline serum albu-
min was ≤ 20 g/L. For patients with baseline serum
albumin >20g/L, there were 15 (50%) study group pa-
tients and 14 (32%) control group patients who died
within 28 days (RR, 2.14; 95% CI, 0.82–5.58; p=0.18).
Albumin administration resulted in no significant differ-
ence in the 28-day mortality rate in patients with base-
line albumin concentration > 20 g/L.
Univariate analysis showed that variables such as di-
agnosis (infection site or source), operation (type of
surgery) and type of cultured bacteria had p > 0.10 on
the risk of 28-day mortality. These variables were not
analyzed further using multivariate analysis. In the group
of patients with baseline serum albumin ≤ 20 g/L,
univariate analysis showed that the variables of age,
APACHE II, SOFA, MODS and frequency of septic
shock had p < 0.1. In the group of patients with base-
line serum albumin >20g/L, univariate analysis showed
that APACHE II, SOFA, MODS and frequency of
septic shock, respiratory dysfunction and renal dysfunc-
tion had p < 0.1. These variables were further analyzed
using multivariate analysis. Table 3 shows the results
of univariate analysis of all the baseline characteristics
that might affect the risk of 28-day mortality in the 2
groups of patients.
Table 4 shows the results of multivariate analysis
of the variables that might affect 28-day mortality after
univariate regression with p < 0.10 in the 2 groups of
patients. We found that albumin administration reduced
28-day mortality in patients whose baseline serum albu-
min was ≤ 20 g/L (odds ratio, 0.203; 95% CI, 0.049–
0.844; p = 0.028); but no such effect was found in
patients whose baseline serum albumin was > 20 g/L
(OR, 1.995; 95% CI, 0.607–6.555; p = 0.255).
The probability of survival in the study and control
groups with baseline albumin concentration ≤ 20 g/L
is shown in the Kaplan–Meier curves (Figure 1). The
study group was associated with a significantly higher
probability of survival (p = 0.002, log-rank test). The
probabilities of survival in the study and control groups
with baseline albumin concentration >20g/L are shown
in Figure 2. No significant difference in probability of
survival was found between the study and control
groups (p = 0.08, log-rank test).
Discussion
In this study, we found no significant difference in the
28-day and hospital mortalities between the study and
control groups (p = 1.00 and p = 0.96, respectively) if
the patients were not stratified according to their
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Table 1. Clinical characteristics of the patients*
Control group Study group
Baseline serum albumin concentration ≤ 20 g/L
Patients (n) 37 22
Plasma albumin at admission (g/L) 16.9 ± 2.8 16.7 ± 2.3
Total albumin in first 7 d (g) 15 ± 18† 90 ± 22
Fresh frozen plasma transfusion 30 (81) 19 (86)
Age (yr) 70.9 ± 14.6 71.8 ± 14.4
Male 22 (60) 16 (73)
Admission APACHE II 22.7 ± 5.8 21.6 ± 5.7
Admission SOFA 9.9 ± 2.9 9.1 ± 3.2
Admission MODS 7.0 ± 2.8 6.6 ± 2.8
Comorbidity 33 (89) 20 (91)
Cardiovascular disease 11 (30) 9 (41)
Chronic respiratory disease 6 (16) 5 (23)
Chronic hepatic disease 8 (22) 6 (27)
Chronic renal failure 7 (19) 6 (27)
Diabetes mellitus 14 (38) 8 (36)
Organs with acute dysfunction
Shock 32 (87) 15 (68)
Respiratory dysfunction 34 (92) 21 (96)
Renal dysfunction 18 (49) 13 (59)
Hematologic dysfunction 16 (43) 8 (36)
Hepatic dysfunction 8 (22) 3 (14)
Referred from
ER 15 (41) 8 (36)
Ward 16 (43) 9 (41)
MICU 6 (16) 5 (23)
Baseline serum albumin concentration > 20 g/L
Patients (n) 44 30
Plasma albumin at admission (g/L) 25.7 ± 4.3 25.1 ± 3.8
Total albumin in first 7 d (g) 6.5 ± 13† 111 ± 54
Age (yr) 78.9 ± 12.4 76.5 ± 13.2
Male 23 (52) 15 (50)
Admission APACHE II 22.2 ± 7.2 21.0 ± 7.0
Admission SOFA 8.5 ± 2.7 9.3 ± 3.0
Admission MODS 5.9 ± 2.2 6.5 ± 2.1
Comorbidity 42 (96) 28 (93)
Cardiovascular disease 32 (73) 20 (67)
Chronic respiratory disease 7 (16) 7 (23)
Chronic hepatic disease 5 (11) 7 (23)
Chronic renal failure 8 (18) 6 (20)
Diabetes mellitus 14 (32) 12 (40)
Organs with acute dysfunction
Shock 27 (61) 22 (73)
Respiratory dysfunction 32 (73) 28 (93)
Renal dysfunction 26 (59) 23 (77)
Hematologic dysfunction 10 (23) 13 (43)
Hepatic dysfunction 6 (14) 5 (17)
Referred from
ER 8 (18) 4 (13)
Ward 29 (66) 15 (50)
MICU 7 (16) 11 (37)
*Data presented as mean ± standard deviation or n (%); †p < 0.05. APACHE II = Acute Physiology and Chronic Health Evaluation II score; SOFA = Sequential
Organ Failure Assessment score; MODS = Multiple Organ Dysfunction Score; ER = emergency room; MICU = medical intensive care unit.
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Table 2. The 28-day mortality of the patients
Control group Study group RR (95% CI) p
All patients
42 (50%) 25 (51%) 1.04 (0.52–2.11) 1.00
Baseline serum albumin concentration ≤ 20 g/L
28 (76%) 10 (45%) 0.27 (0.09–0.83) 0.03
Baseline serum albumin concentration > 20 g/L
14 (32%) 15 (50%) 2.14 (0.82–5.58) 0.18
RR = relative risk; CI = confidence interval.
baseline albumin concentration on admission (Table 2).
Follow-up analysis of the SAFE study25 gave us the
idea to further stratify our patients in each group into
2 subgroups: baseline serum albumin concentration
≤ 20 g/L and baseline serum albumin concentration
> 20 g/L. The result of this stratification showed that
albumin could reduce 28-day mortality in patients with
secondary peritonitis and severe sepsis whose baseline
serum albumin concentration was ≤20g/L, and that no
difference was found in the 28-day mortality rate be-
tween the study and control groups in patients with
baseline serum albumin concentration > 20 g/L. Using
multivariate analysis, we found that septic shock was
more important than other confounding factors in the
determination of 28-day mortality no matter which
baseline albumin group the patient belonged to. In
the SAFE study, no significant difference in all-cause
mortality at 28 days was found between the albumin
group and non-albumin group irrespective of their
baseline albumin concentration. Our result was incon-
sistent with the SAFE study for 28-day survival in pa-
tients whose baseline serum albumin concentration
was ≤ 20 g/L. The different patient entity and different
baseline albumin cut-off point might partly explain
this discrepancy.
Why would albumin administration only benefit pa-
tients with extremely low baseline serum albumin con-
centration? The reason might be that plasma oncotic
pressure should be maintained at a suitable level so as
to maintain homeostasis. If the patient’s plasma albu-
min concentration has declined below that level, then
the administration of exogenous albumin might have
positive effects on the restoration of homeostasis. How-
ever, if the patient’s plasma albumin concentration is
already beyond that level, then it is possible that exoge-
nous albumin may cause detrimental effects. Several
reasons might account for why albumin supplementa-
tion could make things worse for critically ill patients.
First, cardiac decompensation might occur after rapid
volume expansion with 20% albumin, which might lead
to an increase in volume retention up to four-fold.26
Indeed, a previous study in baboons found that inter-
stitial pulmonary edema developed after albumin in-
fusion in hemorrhagic shock.27 Second, in patients
with increased capillary permeability or capillary leak
syndrome, albumin administration may become det-
rimental when albumin and water cross the capillary
membrane and cause or worsen pulmonary edema,
compromising tissue oxygenation and leading to mul-
tiorgan failure. Third, the anti-hemostatic and platelet-
lowering properties of albumin may increase blood loss
in post-surgical or trauma patients.28 Finally, albumin
administration during resuscitation of hypovolemic
shock may impair sodium and water excretion and
worsen renal function.29
Although FFP has an oncotic effect and most sur-
geons prefer using FFP in patients with secondary
peritonitis, our study did not find any significant dif-
ference in mortality rate due to FFP infusion. Our
result was in accordance with the systematic review of
Stanworth et al.30 Transfusion of FFP was even said
to be associated with an increased risk of infection in
critically ill patients.31 Thus, it is not surprising that we
found no significant difference in mortality rate after
FFP infusion.
Elderly patients are at risk of developing severe
sepsis after contraction of secondary peritonitis. Anaya
and Nathens13 showed that patients with severe sepsis
due to secondary peritonitis were significantly older
(68 ± 19 years vs. 46 ± 25 years; p < 0.001) and more
likely to have pre-existing illnesses than those without
severe sepsis. Our results were consistent with their’s
because patients with both secondary peritonitis and
severe sepsis in this study had higher 28-day and hos-
pital mortality rates (50% and 58%, respectively) than
those with either severe sepsis alone5–8 or secondary
peritonitis alone.
It has been shown that the most common cause of
peritonitis is a perforated appendix; however, most cases
of peritonitis due to perforated appendix is localized and
rarely develops into severe sepsis.13 Similarly, we found
that no patient with severe sepsis due to secondary
peritonitis had appendiceal perforation. It has also
been shown that the 3 most common presenting symp-
toms of severe sepsis are respiratory system dysfunction,
shock and renal system dysfunction.6,8 Our findings
were consistent with these reports.
The potential weaknesses of this study were the
limited case number and retrospective methodology.
Moreover, although the Bureau of National Health
Insurance of Taiwan had established the criteria for
albumin administration, in most circumstances, the pa-
tient’s condition did not meet the criteria for albumin
administration when the physician in charge felt that
albumin administration was necessary for the patient’s
good. In that case, albumin administration could be at
the patient’s own expense. The reasons for why some pa-
tients who had secondary peritonitis and severe sepsis
did not receive albumin administration might include
the financial consideration of the family, the hopeless
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Table 3. Univariate analysis of baseline characteristics for the risk of 28-day mortality
RR (95% CI) p
Baseline serum albumin concentration ≤ 20 g/L
Plasma albumin at admission (g/L) 0.508 (0.059–4.377) 0.537
Fresh frozen plasma transfusion 1.354 (0.311–5.901) 0.686
Age (yr) 1.041 (1.000–1.083) 0.051*
Male 1.167 (0.380–3.580) 0.788
Admission APACHE II 1.097 (0.993–1.211) 0.069*
Admission SOFA 1.551 (1.204–1.998) 0.001*
Admission MODS 1.533 (1.169–2.010) 0.002*
Comorbidity
Cardiovascular disease 1.040 (0.337–3.213) 0.946
Chronic respiratory disease 1.600 (0.375–6.820) 0.525
Chronic hepatic disease 1.518 (0.411–5.607) 0.531
Chronic renal failure 0.565 (0.161–1.976) 0.371
Diabetes mellitus 0.508 (0.170–1.519) 0.225
Organs with acute dysfunction
Shock 8.750 (2.028–37.749) 0.004*
Respiratory dysfunction 6.167 (0.599–63.520) 0.126
Renal dysfunction 2.492 (0.834–7.447) 0.102
Hematologic dysfunction 1.619 (0.534–4.913) 0.395
Hepatic dysfunction 2.948 (0.573–15.163) 0.196
Baseline serum albumin concentration > 20 g/L
Plasma albumin at admission (g/L) 0.301 (0.083–1.088) 0.067*
Fresh frozen plasma transfusion 0.781 (0.191–3.189) 0.731
Age (yr) 1.025 (0.984–1.067) 0.239
Male 0.618 (0.214–1.586) 0.317
Admission APACHE II 1.086 (1.010–1.107) 0.025*
Admission SOFA 1.203 (1.007–1.437) 0.042*
Admission MODS 1.285 (1.020–1.619) 0.033*
Comorbidity
Cardiovascular disease 2.155 (0.714–6.267) 0.177
Chronic respiratory disease 0.833 (0.249–2.392) 0.768
Chronic hepatic disease 0.740 (0.201–2.704) 0.651
Chronic renal failure 2.476 (0.738–8.090) 0.133
Diabetes mellitus 0.954 (0.358–2.540) 0.925
Organs with acute dysfunction
Shock 3.840 (1.242–11.872) 0.019*
Respiratory dysfunction 3.000 (1.100–8.180) 0.032*
Renal dysfunction 2.801 (0.955–8.214) 0.061*
Hematologic dysfunction 1.296 (0.476–3.525) 0.612
Hepatic dysfunction 0.869 (0.230–3.278) 0.835
*p < 0.1. RR = relative risk; CI = confidence interval; APACHE II = Acute Physiology and Chronic Health Evaluation II score; SOFA = Sequential Organ Failure
Assessment score; MODS = Multiple Organ Dysfunction Score.
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Table 4. Multivariate analysis of assigned group and baseline characteristics with risk of 28-day mortality
RR (95% CI) p
Baseline serum albumin concentration ≤ 20 g/L
Study vs. control group 0.203 (0.049–0.844) 0.028*
Age 1.051 (1.004–1.101) 0.034*
APACHE II 0.958 (0.821–1.117) 0.584
SOFA 1.495 (1.131–1.975) 0.005*
MODS 1.602 (0.767–3.346) 0.210
Shock 7.965 (1.467–43.254) 0.016*
Baseline serum albumin concentration > 20 g/L
Study vs. control group 1.995 (0.607–6.555) 0.255
Albumin at admission 0.296 (0.064–1.365) 0.119
APACHE II 1.079 (1.003–1.162) 0.042*
SOFA 0.836 (0.560–1.246) 0.378
MODS 1.269 (0.753–2.139) 0.371
Shock 3.572 (1.122–11.373) 0.031*
Respiratory dysfunction 0.827 (0.195–3.497) 0.796
Renal dysfunction 2.662 (0.765–9.264) 0.124
*p < 0.05. RR = relative risk; CI = confidence interval; APACHE II = Acute Physiology and Chronic Health Evaluation II score; SOFA = Sequential Organ Failure
Assessment score; MODS = Multiple Organ Dysfunction Score.
prognosis of the patient’s disease, and the personal pref-
erence of the physician in charge. These factors might
influence the mortality rate of the patients. Neverthe-
less, our findings suggest that intravenous human albu-
min could be administered with possible benefit to
patients with severe sepsis and secondary peritonitis
whose plasma albumin concentration is extremely low.
In conclusion, intravenous administration of human
albumin may reduce 28-day mortality in the small sub-
set of ICU patients who contract secondary peritonitis
and severe sepsis, with an extremely low baseline serum
albumin concentration. However, in patients with sec-
ondary peritonitis and severe sepsis whose baseline
serum albumin is > 20 g/L, albumin administration is
not recommended, as indicated in previous studies.
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Figure 1. Kaplan–Meier estimates of the probability of survival
for baseline albumin concentration of ≤ 20 g/L. The figure shows
the probability of survival in the study and control groups with
baseline albumin concentration of ≤ 20 g/L within 60 days. The
study group was associated with a significantly higher probability
of survival (p = 0.002, log rank test).
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Figure 2. Kaplan–Meier estimates of the probability of survival for
baseline albumin concentration > 20 g/L. The figure shows the
probability of survival in the study and control groups with base-
line albumin concentration > 20 g/L within 60 days. There was no
significant difference in probability of survival between the study
and control groups (p = 0.08, log rank test).
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